← Back to Search

Device

Prostate Cancer Imaging With Radioactive Tracer and Ultrasound Detector Compared to MRI and ProstaScint

Phase < 1
Waitlist Available
Led By Benjamin Franc, MD
Research Sponsored by Radiological Associates of Sacramento Medical Group Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within on month of scan and corresponding mri
Awards & highlights
No Placebo-Only Group

Summary

This is a small study to determine if probe, similar to an ultrasound probe, can detect prostate cancer more specifically than other imaging studies in patients with a positive prostate cancer biopsy.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within on month of scan and corresponding mri
This trial's timeline: 3 weeks for screening, Varies for treatment, and within on month of scan and corresponding mri for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Detection of PSMA antibody (ProstaScint)uptake patterns measured by Proxiscan in comparison with anatomic biopsy reports, conventional SPECT and MRI scans within one month of Proxiscan

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Active Control
Group I: No interventionActive Control1 Intervention
All consenting patients will be imaged with the Proxiscan and data compared with MRI, ProstaScint and biopsy data

Find a Location

Who is running the clinical trial?

Hybridyne Imaging TechnologiesUNKNOWN
Radiological Associates of Sacramento Medical Group Inc.Lead Sponsor
Benjamin Franc, MDPrincipal InvestigatorRadiological Associates of Sacramento Medical Group Inc.
~1 spots leftby Dec 2025